Ontology highlight
ABSTRACT: Purpose
To evaluate the association of five different polymorphisms from a genome-wide-associated study with susceptibility to glaucoma in the northeast Iranian population.Methods
Hundred and thirty patients with primary angle closure glaucoma (PACG) and 130 healthy controls were genotyped for the polymorphic regions with the aid of tetra-amplification refractory mutation system-polymerase chain reaction. The association of these variants with the disease susceptibility was measured statistically with the logistic regression method.Results
Hundred and thirty patients with PACG (53 males, 77 females) with a mean age of 64.5 ± 6.2 years and 130 healthy control subjects (51 males, 79 females) with a mean age of 64.0 ± 5.7 years were selected for evaluation. There was a significant association between rs3816415 (P = 0.005), rs736893 (P < 0.001), rs7494379 (P < 0.001), and rs1258267 (P = 0.02) with PACG susceptibility. This association could not be shown for rs3739821.Conclusion
It was revealed that studied variants in GLIS3, EPDR1, FERMT2, and CHAT genes can contribute to the incidence of PACG. Additional studies in other populations are needed to evaluate DPM2-FAM102A.
SUBMITTER: Yousefian A
PROVIDER: S-EPMC7001019 | biostudies-literature | 2020 Jan-Mar
REPOSITORIES: biostudies-literature
Yousefian Ali A Shokoohi-Rad Saeed S Abbaszadegan Mohammad Reza MR Rad Dorsa Morshedi DM Zargari Selma S Milanizadeh Saman S Morovatdar Negar N Daneshvar Ramin R
Journal of ophthalmic & vision research 20200101 1
<h4>Purpose</h4>To evaluate the association of five different polymorphisms from a genome-wide-associated study with susceptibility to glaucoma in the northeast Iranian population.<h4>Methods</h4>Hundred and thirty patients with primary angle closure glaucoma (PACG) and 130 healthy controls were genotyped for the polymorphic regions with the aid of tetra-amplification refractory mutation system-polymerase chain reaction. The association of these variants with the disease susceptibility was measu ...[more]